Skip to main content
Premium Trial:

Request an Annual Quote

New York Genome Center Buys Illumina HiSeq X Ten


A week after Illumina announced its new high-throughput sequencing platform, the HiSeq X Ten, the New York Genome Center said it has purchased one of the systems.

Bob Darnell, NYGC's CEO, president, and scientific director, told In Sequence that the decision to acquire the HiSeq X Ten resulted from the necessity to move from exome sequencing to whole-genome sequencing in order to be able to capture disease-causing mutations that would otherwise be missed. "The future is being more comprehensive," he said.

The center expects the new instruments to arrive by the end of March, according to Darnell. Initially, they will be mostly used for work by members of the New York Genome Center, but longer term the center plans to engage in academic collaborations to make full use of the system's capacity, he said.

Each of the 10 units can generate about 1.8 terabases of data in under three days, or 15 human genomes at high coverage, so the theoretical output of the system is more than 18,000 genomes per year, at a cost of under $1,000 per genome, according to Illumina.

Illumina sells the instrument in sets of 10 for a total of $10 million, and customers are only permitted to use the HiSeq X Ten for human whole-genome sequencing.

Other than the NYGC, the first customers are the Broad Institute, the Garvan Institute in Australia, and Macrogen in Korea.

Illumina said it can ship the HiSeq X Ten to up to five customers this year, though it might be able to increase its manufacturing capacity to accommodate more customers.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.